Focused On-demand Library for Small ribosomal subunit protein uS15m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P82914

UPID:

RT15_HUMAN

Alternative names:

28S ribosomal protein S15, mitochondrial

Alternative UPACC:

P82914; B2RD82; Q9H2K1

Background:

The Small ribosomal subunit protein uS15m, also known as 28S ribosomal protein S15, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is involved in the synthesis of proteins within the mitochondria, a process essential for cellular energy production and metabolic functions. The protein's unique structure and function within the mitochondrial ribosome make it a subject of interest for understanding mitochondrial biology and its impact on cellular health.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein uS15m could open doors to potential therapeutic strategies. Its critical function in protein synthesis within mitochondria highlights its importance in cellular metabolism and energy production, suggesting that targeting this protein could offer new avenues for treating diseases related to mitochondrial dysfunction.